GoodRx Holdings (GDRX) Total Non-Current Liabilities (2019 - 2026)

GoodRx Holdings has reported Total Non-Current Liabilities for 8 years, with the latest figure at $1.4 billion in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 119.33% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 119.33% YoY) and the FY2025 annual result came in at $779.1 million, up 18.64% from the prior year.
• Total Non-Current Liabilities improved to $1.4 billion in Q1 2026 per GDRX's latest filing, from $779.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $1.4 billion in Q1 2026 and troughed at $634.0 million in Q1 2025.
• A 5-year average of $786.8 million and a median of $776.0 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities decreased 22.16% in 2025, then jumped 119.33% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $782.2 million in 2022, then rose by 4.66% to $818.7 million in 2023, then slipped by 19.79% to $656.7 million in 2024, then climbed by 18.64% to $779.1 million in 2025, then surged by 78.49% to $1.4 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.4 billion, $779.1 million, and $717.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.